While the overwhelming majority of presymptomatic studies focus on C9orf72 hexanucleotide carriers (183, 185–187), no prognostic markers have been validated to predict whether single patients will develop ALS or FTD. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.